Elsevier

Biochemical Pharmacology

Volume 78, Issue 10, 15 November 2009, Pages 1289-1297
Biochemical Pharmacology

Commentary
Regulator of G-protein signaling (RGS) proteins in cancer biology

https://doi.org/10.1016/j.bcp.2009.06.028Get rights and content

Abstract

The regulator of G-protein signaling (RGS) family is a diverse group of multifunctional proteins that regulate cellular signaling events downstream of G-protein coupled receptors (GPCRs). In recent years, GPCRs have been linked to the initiation and progression of multiple cancers; thus, regulators of GPCR signaling are also likely to be important to the pathophysiology of cancer. This review highlights recent studies detailing changes in RGS transcript expression during oncogenesis, single nucleotide polymorphisms in RGS proteins linked to lung and bladder cancers, and specific roles for RGS proteins in multiple cancer types.

Introduction

Cancer is characterized by the uncontrolled growth of cells through increased proliferation and decreased apoptosis. Additionally, cancer cells can invade adjacent tissues and metastasize to non-adjacent organs and tissues. Uncontrolled growth, invasion, and metastasis are due to changes in cellular signaling pathways, and oncogenic transformation is often the direct result of mutations of the signaling molecules which constitute these pathways. In the past decade, G-protein coupled receptor (GPCR)-stimulated pathways have emerged as critical mediators of oncogenic signaling. GPCRs are a family of cell surface receptors which activate heterotrimeric G-proteins to transduce extracellular signals into the interior of a cell. Regulators of G-protein signaling (RGS) proteins are a highly diverse family of proteins containing an RGS domain which accelerates the deactivation of heterotrimeric G-proteins, thus modulating signaling initiated by GPCRs. There are over 20 mammalian RGS proteins ranging from small proteins comprised solely of an RGS domain to multi-domain proteins with functions in multiple signaling pathways. These additional domains serve to mediate interactions with other signaling proteins, allowing RGS proteins to serve as signaling scaffolds. This review examines recent studies focused on the involvement of RGS proteins in the initiation and progression of cancer.

Section snippets

G-protein signaling in cancer biology

G-protein coupled receptors (GPCRs) are known to mediate a wide variety of physiological processes, including sensory perception, immune responses, neurotransmission, and cardiovascular activity. Consequently, GPCRs are also linked to many disease states and serve as direct and indirect targets for roughly half of pharmaceuticals currently on the market [1]. GPCRs function to mediate ligand-dependent activation of heterotrimeric guanine nucleotide binding proteins (G-proteins). Heterotrimeric

RGS proteins regulate G-protein signaling

GPCRs and G-proteins mediate a wide variety of signals and their activity is finely tuned by multiple regulatory proteins. One critical regulatory point in the G-protein cycle is the deactivation of G-proteins by GTP hydrolysis which is enhanced by GTPase activating proteins (GAPs) (Fig. 1). A group of proteins which function as heterotrimeric G-protein GAPs were identified over a decade ago in yeast, worms, and mammals and termed Regulator of G-protein Signaling proteins. Each RGS protein

Changes in expression of RGS transcripts and proteins in oncogenesis

The transformation of normal cells into cancerous cells requires concerted changes in the expression of multiple genes. These genetic changes result in the activation of proto-oncogenes and the inactivation of tumor suppressor genes allowing unregulated cell growth. Many recent studies have attempted to identify proto-oncogenes and tumor suppressors using multiplex gene microarray technology to compare the genetic profiles of matched samples of cancerous and normal tissues. Multiple RGS

RGS protein function in cancer

In addition to correlative studies demonstrating that changes in RGS gene expression are linked to cancer, there have also been several studies demonstrating functions of RGS proteins in cancer.

Conclusions

In the past decade, GPCRs and their cognate ligands have been shown to play a significant role in the initiation and progression of cancer; consequently, it is likely that regulators of GPCRs are also important to the regulation of oncogenic pathways. In this review, we present evidence that the RGS family of proteins play a role in multiple types of cancer. The transcription of over a dozen RGS genes is altered during oncogenesis and mutations in RGS genes have been shown to confer a reduced

References (123)

  • H. Zhong et al.

    A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protein-mediated kinetic scaffolding

    J Biol Chem

    (2003)
  • W. Zeng et al.

    The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling

    J Biol Chem

    (1998)
  • R.J. Kimple et al.

    RGS12 and RGS14 GoLoco motifs are G alpha(i) interaction sites with guanine nucleotide dissociation inhibitor activity

    J Biol Chem

    (2001)
  • L.S. Bernstein et al.

    RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling

    J Biol Chem

    (2004)
  • J.H. Hurst et al.

    Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells

    Cell Signal

    (2008)
  • X. Chen et al.

    Novel endothelial cell markers in hepatocellular carcinoma

    Mod Pathol

    (2004)
  • A.P. Silva et al.

    Identification of 9 novel transcripts and two RGSL genes within the hereditary prostate cancer region (HPC1) at 1q25

    Gene

    (2003)
  • R. Sood et al.

    Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus

    Genomics

    (2001)
  • J. Schwable et al.

    RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation

    Blood

    (2005)
  • D.G. Gilliland et al.

    The roles of FLT3 in hematopoiesis and leukemia

    Blood

    (2002)
  • K. Burridge et al.

    Rho and Rac take center stage

    Cell

    (2004)
  • A.A. Schmitz et al.

    Rho GTPases: signaling, migration, and invasion

    Exp Cell Res

    (2000)
  • F.M. Vega et al.

    Rho GTPases in cancer cell biology

    FEBS Lett

    (2008)
  • Q. Wang et al.

    Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells

    J Biol Chem

    (2004)
  • D. Hanahan et al.

    Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

    Cell

    (1996)
  • K.L. Pierce et al.

    Seven-transmembrane receptors

    Nat Rev Mol Cell Biol

    (2002)
  • S. Li et al.

    Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression

    Int J Oncol

    (2005)
  • R.T. Dorsam et al.

    G-protein-coupled receptors and cancer

    Nat Rev Cancer

    (2007)
  • J.S. Gutkind

    Cell growth control by G protein-coupled receptors: from signal transduction to signal integration

    Oncogene

    (1998)
  • D. Julius et al.

    Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation

    Science

    (1989)
  • G.B. Mills et al.

    The emerging role of lysophosphatidic acid in cancer

    Nat Rev Cancer

    (2003)
  • P. Rodien et al.

    Activating mutations of TSH receptor

    Ann Endocrinol (Paris)

    (2003)
  • P. Arora et al.

    Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer

    J Cell Sci

    (2007)
  • E. Rozengurt et al.

    Gastrointestinal peptide signalling in health and disease

    Eur J Surg Suppl

    (2002)
  • T. Kijima et al.

    Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells

    Cancer Res

    (2002)
  • L. Arvanitakis et al.

    Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation

    Nature

    (1997)
  • S.J. Paulsen et al.

    Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor

    J Virol

    (2005)
  • H. Zhang et al.

    Dual Activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo

    Cancer Res.

    (2009)
  • X. Cao et al.

    Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells

    Oncogene

    (2006)
  • J.S. Biscardi et al.

    Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer

    Breast Cancer Res

    (2000)
  • A.W. Burgess

    EGFR family: structure physiology signalling and therapeutic targets

    Growth Factors

    (2008)
  • F. Ciardiello et al.

    A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor

    Clin Cancer Res

    (2001)
  • J. Mendelsohn

    The epidermal growth factor receptor as a target for cancer therapy

    Endocr Relat Cancer

    (2001)
  • J. Baselga et al.

    HER-targeted tyrosine-kinase inhibitors

    Oncology

    (2002)
  • O.M. Fischer et al.

    EGFR signal transactivation in cancer cells

    Biochem Soc Trans

    (2003)
  • L. Vallar et al.

    Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas

    Nature

    (1987)
  • V. Radhika et al.

    Transforming G proteins

    Oncogene

    (2001)
  • J. Lyons et al.

    Two G protein oncogenes in human endocrine tumors

    Science

    (1990)
  • N. Sakai et al.

    Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation

    Neurol Med Chir (Tokyo)

    (2008)
  • C.A. Landis et al.

    GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours

    Nature

    (1989)
  • Cited by (134)

    • Bioinformatics analysis identified RGS4 as a potential tumor promoter in glioma

      2022, Pathology Research and Practice
      Citation Excerpt :

      RGS protein are associated with the occurrence and development of cancer [44]. It has been reported that RGS4 is a newly discovered powerful glioma cell aggressiveness driving molecule [45]. Moreover, numerous RGS proteins are expressed in different regions of the brain [46], and it has been demonstrated that RGS proteins potentially serve an important rolee in the regulation of neuronal signaling pathways.

    View all citing articles on Scopus
    View full text